Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Merit Medical (MMSI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 8% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
PDCO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Amedisys (AMED) to Advance Value-Based Care With Optum Merger
by Zacks Equity Research
Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.
Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Inspire Medical's (INSP) global presence.
Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients
by Zacks Equity Research
Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.
Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.
Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.
Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure
by Zacks Equity Research
Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.
Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio
by Zacks Equity Research
Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.
PDCO vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Masimo's (MASI) Launch to Serve the Personalized Hearables Market
by Zacks Equity Research
Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Patterson Companies (PDCO) Q4 Earnings Beat, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2023 results reflect robust improvement in Dental Equipment sales, Value-added services and Animal Health segment.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) owing to strength in Omnipod 5 and its focus on market expansion.
QIAGEN's (QGEN) ForenSeq MainstAY Workflow Gets FBI Nod
by Zacks Equity Research
QIAGEN's (QGEN) ForenSeq MainstAY workflow is a cost-effective substitute for analyzing short tandem repeats with capillary electrophoresis and facilitates volume casework for sexual assault cases.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering
by Zacks Equity Research
Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.
Align's (ALGN) Invisalign Sales Grow Globally Amid Margin Woe
by Zacks Equity Research
Align (ALGN) is confident about a largely untapped market opportunity for digital orthodontics and restorative dentistry.
3 Reasons to Add HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
PacBio's (PACB) New Tie-Up to Boost Rare Disease Research
by Zacks Equity Research
PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.